Allarity Therapeutics Inc (ALLR)vsAlnylam Pharmaceuticals Inc (ALNY)
ALLR
Allarity Therapeutics Inc
$1.12
-1.75%
HEALTHCARE · Cap: $17.28M
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates -52211% more annual revenue ($3.71B vs $-7.13M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALLR trades at a lower P/E of 0.2x. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALLR
Avoid23
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+97.7%
Fair Value
$39.10
Current Price
$1.12
$37.98 discount
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ALLR
The strongest argument for ALLR centers on P/E Ratio, Price/Book.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ALLR
The primary concerns for ALLR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ALLR profiles as a value stock while ALNY is a hypergrowth play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 23/100) and 84.9% revenue growth. ALLR offers better value entry with a 97.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Allarity Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?